Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITBHaic: HAIC + QL1706 + bevacizumab for conversion of potentially resectable HCC
ChiCTR2500107358Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706, bevacizumab and FOLFOX in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoint: Conversion resection rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QL1706bevacizumabFOLFOX
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500107358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107358.